Login / Signup

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.

John B BuseBruce W BodeAnn MertensYoung Min ChoErik ChristiansenChristin L HertzMorten A NielsenThomas R Piebernull null
Published in: BMJ open diabetes research & care (2021)
NCT02849080.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • clinical trial
  • placebo controlled
  • study protocol
  • double blind
  • phase ii study
  • randomized controlled trial
  • locally advanced